Literature DB >> 21424433

[Multiresistant pathogens in surgery].

I F Chaberny1, E Ott.   

Abstract

Nosocomial infections caused by multidrug resistant organism (MDRO) are an increasingly common healthcare-associated problem. In surgery methicillin-resistant Staphylococcus aureus (MRSA) is still the most important of these bacteria, and the management of MRSA infections and the prevention of their nosocomial transmission are a major challenge. Hence, a comprehensive strategy for the prevention of nosocomial MRSA infections is imperative including optimization of antibiotic use in hospital, antibiotic stewardship as well as admission surveillance cultures, and improved compliance of hand hygiene.

Entities:  

Mesh:

Year:  2011        PMID: 21424433     DOI: 10.1007/s00113-011-2015-9

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  30 in total

Review 1.  SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus.

Authors:  Carlene A Muto; John A Jernigan; Belinda E Ostrowsky; Hervé M Richet; William R Jarvis; John M Boyce; Barry M Farr
Journal:  Infect Control Hosp Epidemiol       Date:  2003-05       Impact factor: 3.254

2.  Compliance with antiseptic hand rub use in intensive care units: the Hawthorne effect.

Authors:  Tim Eckmanns; Jan Bessert; Michael Behnke; Petra Gastmeier; Henning Ruden
Journal:  Infect Control Hosp Epidemiol       Date:  2006-08-22       Impact factor: 3.254

3.  Active surveillance screening of MRSA and eradication of the carrier state decreases surgical-site infections caused by MRSA.

Authors:  Walter E Pofahl; Claudia E Goettler; Keith M Ramsey; M Kathy Cochran; Delores L Nobles; Michael F Rotondo
Journal:  J Am Coll Surg       Date:  2009-03-26       Impact factor: 6.113

4.  Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection.

Authors:  Klaus Kaier; Christian Hagist; Uwe Frank; Andreas Conrad; Elisabeth Meyer
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

Review 5.  Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control.

Authors:  I M Gould
Journal:  Int J Antimicrob Agents       Date:  2006-10-11       Impact factor: 5.283

6.  Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment.

Authors:  M H Wernitz; S Keck; S Swidsinski; S Schulz; S K Veit
Journal:  Clin Microbiol Infect       Date:  2005-06       Impact factor: 8.067

7.  Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System).

Authors:  Christine Geffers; Petra Gastmeier
Journal:  Dtsch Arztebl Int       Date:  2011-02-11       Impact factor: 5.594

8.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.

Authors:  John J Engemann; Yehuda Carmeli; Sara E Cosgrove; Vance G Fowler; Melissa Z Bronstein; Sharon L Trivette; Jane P Briggs; Daniel J Sexton; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2003-02-07       Impact factor: 9.079

9.  Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; I Cabezudo; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

10.  Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted time-series analysis.

Authors:  Iris F Chaberny; Frank Schwab; Stefan Ziesing; Sebastian Suerbaum; Petra Gastmeier
Journal:  J Antimicrob Chemother       Date:  2008-09-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.